At a crucial time with rapid spread of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) Omicron variant globally, the United States Food and Drug Administration …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

Background Oral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) have received emergency use authorization for the treatment of mild-to-moderate …

Background Molnupiravir and ritonavir-boosted nirmatrelvir are the two leading oral COVID-
19 antiviral treatments, but their antiviral activities in patients have not been compared …

This study aimed to compare the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) with
molnupiravir in the treatment of coronavirus disease 2019 (COVID‐19). To end this …

Despite the rapid development of efficient and safe vaccines against COVID-19, the need to
confine the pandemic and treat infected individuals on an outpatient basis has led to the …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …